Launch of test to avoid hearing loss in neonates

RNS Number : 8478G

Inspiration Healthcare Group PLC

01 April 2022

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Launch of genetic test to avoid Antibiotic Induced Hearing Loss in neonates

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce the commercial introduction of the Genedrive® MT-RNR1 ID Kit in the UK and Ireland, following the distribution agreement announced in April 2020 with genedrive plc (AIM: GDR).

Inspiration Healthcare will continue its leading position in improving patient outcomes by being one of the first companies in the world to deliver point-of-care genetic testing designed for use in a neonatal intensive care setting. The Genedrive® MT-RNR1 ID Kit screens newborns for a maternally inherited genetic variant termed MT-RNR1 which causes lifelong and irreversible deafness in a child upon administration of certain antibiotics. The goal is to allow screening for all children receiving antibiotics on NICU admission. In the UK, approximately 90,000 babies are admitted to NICU each year, and approximately 80-85% of them receive antibiotics. genedrive's rapid genetic test can be completed in less than 30 minutes, allowing for alternative treatment decision on antibiotics within one hour of admission, a timeline required by the UK's National Institute of Clinical Excellence (NICE) for administration on antibiotics. Inspiration Healthcare has an exclusive distribution agreement with genedrive plc for the Antibiotic Induced Hearing Loss test, with the option to extend the agreement further through its global commercial network.

Neil Campbell, Chief Executive Officer, commented: "We are excited to be involved in this ground-breaking approach for dealing with MT-RNR1 with genedrive. It fits perfectly with our track record of providing innovative solutions to improve the outcomes for neonates."

Enquiries:

Inspiration Healthcare Group plc Neil Campbell, Chief Executive Officer Jon Ballard, Chief Financial Officer	Tel: [phone]
Cadogan PR  Alex Walters [e-mail]	Tel: [phone]

About Inspiration Healthcare Group

www.inspirationhealthcaregroup.plc.uk

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

The Group currently consists of three companies: Inspiration Healthcare Ltd, SLE Ltd and Viomedex Ltd and under these brands the Group sells neonatal intensive care and operating theatre equipment around the work through a network of distributors into over 75 countries.  Products range from highly sophisticated capital equipment through to single use disposables all that can help improve outcomes of extremely sick patients.

In the UK and Ireland the Group offers direct sales for most of its products supported by Technical Service offering on site and return to base repair and maintenance along with 24/7 emergency hire of equipment and long term lease arrangements for its own brand products.  The Group also acts as a distributor for 3 ^rd  party companies that wish to access the NHS using the Group's sales and service expertise and knowledge of the NHS

The Group invests in growth through Research and Development holding numerous patents on its technology and has strong links with academic Key Opinion Leaders around the world and supports clinical research in the field of neonatal intensive care.

Further information on Inspiration Healthcare Group plc can be seen at  www.inspirationhealthcaregroup.plc.uk  

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and a high throughput SARS-CoV-2 assay.  The Company recently released point of care test for Covid-19.

 

END

 

 

NRABLGDXLXXDGDB